<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01490814</url>
  </required_header>
  <id_info>
    <org_study_id>FI-123</org_study_id>
    <nct_id>NCT01490814</nct_id>
  </id_info>
  <brief_title>FIRE AND ICE: Comparative Study of Two Ablation Procedures in Patients With Atrial Fibrillation</brief_title>
  <official_title>A Controlled, Prospective, Non-Inferiority, Parallel-Group, Randomised, Interventional, Open, Blinded Outcome Assessment (PROBE-Design), Multi-centre Trial, Comparing Efficacy and Safety of Isolation of the PVs With a Cryoballoon Catheter vs a Radiofrequency Ablation With a ThermoCool Catheter in Patients With PAF</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medtronic Atrial Fibrillation Solutions</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Medtronic</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Medtronic Atrial Fibrillation Solutions</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Comparing efficacy and safety of isolation of the pulmonary veins (PV) using a Cryoballoon
      catheter versus a radiofrequency ablation with a ThermoCool catheter in patients with
      paroxysmal atrial fibrillation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this randomized clinical trial is to compare the efficacy and safety of
      isolating the PVs with either the cryoballoon or a RF ablation technique with a ThermoCool
      catheter, a system which can be regarded as standard for ablation. In total 762 patients with
      paroxysmal atrial fibrillation has been randomized for either radiofrequency (RF) or
      cryoballoon. With both techniques, PV isolation will be performed. Primary end point of the
      trial is the time to first recurrence of atrial arrhythmias or prescription of
      anti-arrhythmic drugs after a blanking period of three months. Treatment success will be
      evaluated by using weekly electrocardiography (ECG) monitoring (transtelephonic
      transmission/Tele-ECG) and using Holter electrocardiograms.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2011</start_date>
  <completion_date type="Actual">January 2016</completion_date>
  <primary_completion_date type="Actual">January 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Subjects With Recurrence of Atrial Arrhythmias or Prescription of Anti-arrhythmic Drug or Re-ablation After a Blanking Period of Three Months After the Initial Ablation Procedure</measure>
    <time_frame>33 months</time_frame>
    <description>Number of subjects reporting a primary efficacy endpoint</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Subjects With a Primary Safety Event. A Primary Safety Event Includes a Composite of Death (Including Cardiovascular Death), All-cause Stroke/Transient Ischemic Attack (TIA) and Serious Adverse Events of Special Interest.</measure>
    <time_frame>33 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>All-cause Death</measure>
    <time_frame>33 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Arrhythmia-related Death</measure>
    <time_frame>33 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Procedure Duration</measure>
    <time_frame>Through the initial ablation procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Time of Fluoroscopy</measure>
    <time_frame>Fluoroscopy meter time through the initial ablation procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting a Cardiovascular Hospitalization Over the Duration of the Study.</measure>
    <time_frame>33 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Cardiovascular Hospitalizations</measure>
    <time_frame>33 months</time_frame>
    <description>The total number of cardiovascular hospitalizations reported over the duration of the study.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">769</enrollment>
  <condition>Symptomatic Paroxysmal Atrial Fibrillation (PAF)</condition>
  <arm_group>
    <arm_group_label>Cryoballoon ablation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Radiofrequency ablation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Electrical isolation of the pulmonary veins</intervention_name>
    <description>Device: ArcticFront® Cardiac CryoAblation Catheter System with the FlexCath Steerable Sheath or ArcticFront® Advance Cardiac CryoAblation Catheter System with the FlexCath Steerable Sheath or any future development generations of this product line, provided they are CE marked and the centre has the experience of at least 10 procedures before including a patient into the study.</description>
    <arm_group_label>Cryoballoon ablation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Electrical isolation of pulmonary veins</intervention_name>
    <description>Device:NaviStar® ThermoCool® Irrigated Tip Ablation Catheter in combination with 3D mapping system CARTO or any future development generations of this product line, provided they are CE marked and the centre has the experience of at least 10 procedures before including a patient into the study.</description>
    <arm_group_label>Radiofrequency ablation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Symptomatic PAF with at least two episodes and at least one episode documented (30
             seconds episode length, documented by ECG within last 12 months).

          -  Documented treatment failure for effectiveness of at least one anti-arrhythmic
             drug(AAD Type I or III, including β-blocker and AAD intolerance).

          -  ≥ 18 and ≤ 75 years of age.

          -  Patients who are mentally and linguistically able to understand the aim of the trial
             and to show sufficient compliance in following the trial protocol.

          -  Patient is able to verbally acknowledge and understand the associated risks, benefits,
             and treatment alternatives to therapeutic options of this trial: cryoballoon ablation
             system or standard RF ablation technique. The patients, by providing informed consent,
             agree to these risks and benefits as stated in the patient informed consent document.
             All the details have been presented to him and he has signed the informed consent form
             for the trial.

        Exclusion Criteria:

        General exclusion criteria

          -  Any disease that limits life expectancy to less than one year.

          -  Participation in another clinical trial (of a drug, device or biologic), either within
             the past two months or ongoing.

          -  Pregnant women or women of childbearing potential not on adequate birth control: only
             women with a highly effective method of contraception [oral contraception or
             intrauterine device (IUD)] or sterile women can be randomized.

          -  Breastfeeding women.

          -  Substance misuse.

          -  Active systemic infection.

          -  Cryoglobulinaemia.

          -  Previous participation in this clinical trial.

          -  Employment by the sponsor or by the department of any of the investigators.

          -  Close relatives of any of the investigators.

        Exclusion criteria related to a cardiac condition

          -  Patients with prosthetic valves.

          -  Any previous LA ablation or surgery.

          -  Any cardiac surgery or percutaneous coronary intervention (PCI) within three months
             prior to enrollment.

          -  Unstable angina pectoris.

          -  Myocardial infarction within three months prior to enrollment.

          -  Symptomatic carotid stenosis.

          -  Chronic obstructive pulmonary disease with detected pulmonary hypertension.

          -  Any condition contraindicating chronic anticoagulation.

          -  Stroke or transient ischemic attack within six months prior to enrollment.

          -  Any significant congenital heart defect corrected or not (including atrial septal
             defects or PV abnormalities) but not including patent foramen ovale.

          -  New York Heart Association (NYHA) class III or IV congestive heart failure.

          -  EF &lt; 35 % (determined by echocardiography within 60 days of enrollment as documented
             in patient medical history).

          -  Anteroposterior LA diameter &gt; 55 mm (by trans-thoracic echocardiography (TTE or TEE)
             within three months to prior enrollment).

          -  LA thrombus (TEE diagnostic performed on admission).

          -  Intracardiac thrombus.

          -  PV diameter &gt; 26 mm in right sided PVs.

          -  Mitral prosthesis.

          -  Hypertrophic cardiomyopathy (see Appendix IX)

          -  2° (Type II) or 3° atrioventricular block.

          -  Brugada syndrome or long QT syndrome.

          -  Arrhythmogenic right ventricular dysplasia.

          -  Sarcoidosis.

          -  PV stent.

          -  Myxoma.

        Exclusion criteria based on laboratory abnormalities

          -  Thrombocytosis (platelet count &gt; 600,000 / µl), thrombocytopenia (platelet count &lt;
             100,000 / µl).

          -  Any untreated or uncontrolled hyperthyroidism or hypothyroidism.

          -  Severe renal dysfunction (stage V, requiring or almost requiring dialysis, glomerular
             filtration rate (GFR) &lt; 15 ml / min).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Karl-Heinz Kuck, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Asklepios Klinikum St. Georg</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Na Homolce Hospital, Cardiology</name>
      <address>
        <city>Prague</city>
        <zip>515030</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Henri Mondor CHU, Service de Cardiologie</name>
      <address>
        <city>Créteil</city>
        <zip>94010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Lyon, Départment de Rythmologie, Hospital Cardiologique Pradel</name>
      <address>
        <city>Lyon</city>
        <zip>69677</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Chirurgical Ambroise Paré</name>
      <address>
        <city>Neuilly Sur Seine</city>
        <zip>92200</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>La Clinique Pasteur, 45 Avenue de Lombez</name>
      <address>
        <city>Toulouse</city>
        <zip>31076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Herz-Zentrum Bad Krozingen</name>
      <address>
        <city>Bad Krozingen</city>
        <zip>79189</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinik für Kardiologie II mit interventioneller Elektrophysiologie</name>
      <address>
        <city>Bad Neustadt/Saale</city>
        <zip>97616</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cardioangiologisches Centrum Bethanien - CCB</name>
      <address>
        <city>Frankfurt</city>
        <zip>60431</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Greifswald Elektrophysiologie</name>
      <address>
        <city>Greifswald</city>
        <zip>17475</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asklepios Klinik St. Georg</name>
      <address>
        <city>Hamburg</city>
        <zip>20099</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Herz-Zentrum-Bodensee Konstanz</name>
      <address>
        <city>Konstanz</city>
        <zip>78464</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Semmelweis University of Medicine, Kardiovaskuläres Zentrum</name>
      <address>
        <city>Budapest</city>
        <zip>1122</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cardiac Arrhythmia Research Centre Department of Cardiovascular Medicine Centro Cardiologico Monzino University of Milan</name>
      <address>
        <city>Milan</city>
        <zip>20138</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Isala Klinieken loc. Weezenlanden Diagram Clinical Resarch</name>
      <address>
        <city>Zwolle</city>
        <zip>8011</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic, University of Barcelona</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arrhythmia Unit Hospital Clinico San Carlos</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen de la Victoria, Department of Cardiology, Campus Teatinos sn</name>
      <address>
        <city>Malaga</city>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico Universtitario, Cardiology Department Arrhythmia Unit</name>
      <address>
        <city>Valencia</city>
        <zip>46014</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsspital Basel, Elektrophysiologie/ Kardiologie</name>
      <address>
        <city>Basel</city>
        <zip>4031</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Czechia</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Spain</country>
    <country>Switzerland</country>
  </location_countries>
  <removed_countries>
    <country>Belgium</country>
    <country>Czech Republic</country>
    <country>United Kingdom</country>
  </removed_countries>
  <link>
    <url>http://www.ncbi.nlm.nih.gov/pubmed/25146732</url>
    <description>Rationale and Design of FIRE AND ICE: A Multicenter Randomized Trial Comparing Efficacy and Safety of Pulmonary Vein Isolation using a Cryoballoon Versus Radiofrequency Ablation with 3D-reconstruction.</description>
  </link>
  <link>
    <url>http://www.ncbi.nlm.nih.gov/pubmed/27042964</url>
    <description>Cryoballoon or Radiofrequency Ablation for Paroxysmal Atrial Fibrillation.</description>
  </link>
  <link>
    <url>http://www.acc.org/latest-in-cardiology/clinical-trials/2016/04/03/15/28/fire-and-ice</url>
    <description>FIRE AND ICE: LBCT ACC</description>
  </link>
  <reference>
    <citation>Fürnkranz A, Brugada J, Albenque JP, Tondo C, Bestehorn K, Wegscheider K, Ouyang F, Kuck KH. Rationale and Design of FIRE AND ICE: A multicenter randomized trial comparing efficacy and safety of pulmonary vein isolation using a cryoballoon versus radiofrequency ablation with 3D-reconstruction. J Cardiovasc Electrophysiol. 2014 Dec;25(12):1314-20. doi: 10.1111/jce.12529. Epub 2014 Nov 12.</citation>
    <PMID>25146732</PMID>
  </reference>
  <results_reference>
    <citation>Kuck KH, Brugada J, Fürnkranz A, Metzner A, Ouyang F, Chun KR, Elvan A, Arentz T, Bestehorn K, Pocock SJ, Albenque JP, Tondo C; FIRE AND ICE Investigators. Cryoballoon or Radiofrequency Ablation for Paroxysmal Atrial Fibrillation. N Engl J Med. 2016 Jun 9;374(23):2235-45. doi: 10.1056/NEJMoa1602014. Epub 2016 Apr 4.</citation>
    <PMID>27042964</PMID>
  </results_reference>
  <verification_date>March 2018</verification_date>
  <study_first_submitted>December 6, 2011</study_first_submitted>
  <study_first_submitted_qc>December 9, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 13, 2011</study_first_posted>
  <results_first_submitted>February 16, 2017</results_first_submitted>
  <results_first_submitted_qc>March 2, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">November 2, 2018</results_first_posted>
  <last_update_submitted>March 2, 2018</last_update_submitted>
  <last_update_submitted_qc>March 2, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">November 2, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PAF</keyword>
  <keyword>two episodes within the last twelve months one episode documented</keyword>
  <keyword>Documented treatment failure of at least one antiarrhythmic</keyword>
  <keyword>drug AAD Type I or III including β-blocker and AAD intolerance</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>769 subjects were enrolled; 7 subjects exited prior to randomization, 762 were randomized</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Cryoballoon Ablation</title>
          <description>Electrical isolation of the pulmonary veins: Device: ArcticFront® Cardiac CryoAblation Catheter System with the FlexCath Steerable Sheath or ArcticFront® Advance Cardiac CryoAblation Catheter System with the FlexCath Steerable Sheath or any future development generations of this product line, provided they are CE marked and the centre has the experience of at least 10 procedures before including a patient into the study.</description>
        </group>
        <group group_id="P2">
          <title>Radiofrequency Ablation</title>
          <description>Electrical isolation of pulmonary veins: Device:NaviStar® ThermoCool® Irrigated Tip Ablation Catheter in combination with 3D mapping system CARTO or any future development generations of this product line, provided they are CE marked and the centre has the experience of at least 10 procedures before including a patient into the study.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="378">378 subjects randomized to Cryoballoon arm</participants>
                <participants group_id="P2" count="384">384 subjects randomized to radiofrequency arm</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="374">374 received ablation</participants>
                <participants group_id="P2" count="376">376 received ablation</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Inclusion/Exclusion Criteria Violation</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Cryoballoon Ablation</title>
          <description>Electrical isolation of the pulmonary veins: Device: ArcticFront® Cardiac CryoAblation Catheter System with the FlexCath Steerable Sheath or ArcticFront® Advance Cardiac CryoAblation Catheter System with the FlexCath Steerable Sheath or any future development generations of this product line, provided they are CE marked and the centre has the experience of at least 10 procedures before including a patient into the study.</description>
        </group>
        <group group_id="B2">
          <title>Radiofrequency Ablation</title>
          <description>Electrical isolation of pulmonary veins: Device:NaviStar® ThermoCool® Irrigated Tip Ablation Catheter in combination with 3D mapping system CARTO or any future development generations of this product line, provided they are CE marked and the centre has the experience of at least 10 procedures before including a patient into the study.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="374"/>
            <count group_id="B2" value="376"/>
            <count group_id="B3" value="750"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59.9" spread="9.8"/>
                    <measurement group_id="B2" value="60.1" spread="9.2"/>
                    <measurement group_id="B3" value="60.0" spread="9.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="153"/>
                    <measurement group_id="B2" value="140"/>
                    <measurement group_id="B3" value="293"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="221"/>
                    <measurement group_id="B2" value="236"/>
                    <measurement group_id="B3" value="457"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Years since first PAF diagnosis</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.6" spread="5.1"/>
                    <measurement group_id="B2" value="4.7" spread="5.3"/>
                    <measurement group_id="B3" value="4.6" spread="5.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects With Recurrence of Atrial Arrhythmias or Prescription of Anti-arrhythmic Drug or Re-ablation After a Blanking Period of Three Months After the Initial Ablation Procedure</title>
        <description>Number of subjects reporting a primary efficacy endpoint</description>
        <time_frame>33 months</time_frame>
        <population>Subjects randomized and received an ablation procedure. Modified intent-to-treat (mITT) population.</population>
        <group_list>
          <group group_id="O1">
            <title>Cryoballoon Ablation</title>
            <description>Electrical isolation of the pulmonary veins: Device: ArcticFront® Cardiac CryoAblation Catheter System with the FlexCath Steerable Sheath or ArcticFront® Advance Cardiac CryoAblation Catheter System with the FlexCath Steerable Sheath or any future development generations of this product line, provided they are CE marked and the centre has the experience of at least 10 procedures before including a patient into the study.</description>
          </group>
          <group group_id="O2">
            <title>Radiofrequency Ablation</title>
            <description>Electrical isolation of pulmonary veins: Device:NaviStar® ThermoCool® Irrigated Tip Ablation Catheter in combination with 3D mapping system CARTO or any future development generations of this product line, provided they are CE marked and the centre has the experience of at least 10 procedures before including a patient into the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Recurrence of Atrial Arrhythmias or Prescription of Anti-arrhythmic Drug or Re-ablation After a Blanking Period of Three Months After the Initial Ablation Procedure</title>
          <description>Number of subjects reporting a primary efficacy endpoint</description>
          <population>Subjects randomized and received an ablation procedure. Modified intent-to-treat (mITT) population.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="374"/>
                <count group_id="O2" value="376"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="138"/>
                    <measurement group_id="O2" value="143"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects With a Primary Safety Event. A Primary Safety Event Includes a Composite of Death (Including Cardiovascular Death), All-cause Stroke/Transient Ischemic Attack (TIA) and Serious Adverse Events of Special Interest.</title>
        <time_frame>33 months</time_frame>
        <population>Subjects randomized and received an ablation procedure. Modified intent-to-treat (mITT) population.</population>
        <group_list>
          <group group_id="O1">
            <title>Cryoballoon Ablation</title>
            <description>Electrical isolation of the pulmonary veins: Device: ArcticFront® Cardiac CryoAblation Catheter System with the FlexCath Steerable Sheath or ArcticFront® Advance Cardiac CryoAblation Catheter System with the FlexCath Steerable Sheath or any future development generations of this product line, provided they are CE marked and the centre has the experience of at least 10 procedures before including a patient into the study.</description>
          </group>
          <group group_id="O2">
            <title>Radiofrequency Ablation</title>
            <description>Electrical isolation of pulmonary veins: Device:NaviStar® ThermoCool® Irrigated Tip Ablation Catheter in combination with 3D mapping system CARTO or any future development generations of this product line, provided they are CE marked and the centre has the experience of at least 10 procedures before including a patient into the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With a Primary Safety Event. A Primary Safety Event Includes a Composite of Death (Including Cardiovascular Death), All-cause Stroke/Transient Ischemic Attack (TIA) and Serious Adverse Events of Special Interest.</title>
          <population>Subjects randomized and received an ablation procedure. Modified intent-to-treat (mITT) population.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="374"/>
                <count group_id="O2" value="376"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>No primary safety event</title>
                  <measurement_list>
                    <measurement group_id="O1" value="334"/>
                    <measurement group_id="O2" value="325"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Death</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>All-cause stroke or TIA</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Atrial Arrhythmia</title>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Non-arrhythmia-related Serious Adverse Event</title>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                    <measurement group_id="O2" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>All-cause Death</title>
        <time_frame>33 months</time_frame>
        <population>Subjects randomized and received ablation. Modified intent-to-treat (mITT) population.</population>
        <group_list>
          <group group_id="O1">
            <title>Cryoballoon Ablation</title>
            <description>Electrical isolation of the pulmonary veins: Device: ArcticFront® Cardiac CryoAblation Catheter System with the FlexCath Steerable Sheath or ArcticFront® Advance Cardiac CryoAblation Catheter System with the FlexCath Steerable Sheath or any future development generations of this product line, provided they are CE marked and the centre has the experience of at least 10 procedures before including a patient into the study.</description>
          </group>
          <group group_id="O2">
            <title>Radiofrequency Ablation</title>
            <description>Electrical isolation of pulmonary veins: Device:NaviStar® ThermoCool® Irrigated Tip Ablation Catheter in combination with 3D mapping system CARTO or any future development generations of this product line, provided they are CE marked and the centre has the experience of at least 10 procedures before including a patient into the study.</description>
          </group>
        </group_list>
        <measure>
          <title>All-cause Death</title>
          <population>Subjects randomized and received ablation. Modified intent-to-treat (mITT) population.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="374"/>
                <count group_id="O2" value="376"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Arrhythmia-related Death</title>
        <time_frame>33 months</time_frame>
        <population>Subjects randomized and received an ablation procedure. Modified intent-to-treat (mITT) population.</population>
        <group_list>
          <group group_id="O1">
            <title>Cryoballoon Ablation</title>
            <description>Electrical isolation of the pulmonary veins: Device: ArcticFront® Cardiac CryoAblation Catheter System with the FlexCath Steerable Sheath or ArcticFront® Advance Cardiac CryoAblation Catheter System with the FlexCath Steerable Sheath or any future development generations of this product line, provided they are CE marked and the centre has the experience of at least 10 procedures before including a patient into the study.</description>
          </group>
          <group group_id="O2">
            <title>Radiofrequency Ablation</title>
            <description>Electrical isolation of pulmonary veins: Device:NaviStar® ThermoCool® Irrigated Tip Ablation Catheter in combination with 3D mapping system CARTO or any future development generations of this product line, provided they are CE marked and the centre has the experience of at least 10 procedures before including a patient into the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Arrhythmia-related Death</title>
          <population>Subjects randomized and received an ablation procedure. Modified intent-to-treat (mITT) population.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="374"/>
                <count group_id="O2" value="376"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Procedure Duration</title>
        <time_frame>Through the initial ablation procedure</time_frame>
        <population>Subjects randomized and received ablation. Modified intent-to-treat (mITT) population.</population>
        <group_list>
          <group group_id="O1">
            <title>Cryoballoon Ablation</title>
            <description>Electrical isolation of the pulmonary veins: Device: ArcticFront® Cardiac CryoAblation Catheter System with the FlexCath Steerable Sheath or ArcticFront® Advance Cardiac CryoAblation Catheter System with the FlexCath Steerable Sheath or any future development generations of this product line, provided they are CE marked and the centre has the experience of at least 10 procedures before including a patient into the study.</description>
          </group>
          <group group_id="O2">
            <title>Radiofrequency Ablation</title>
            <description>Electrical isolation of pulmonary veins: Device:NaviStar® ThermoCool® Irrigated Tip Ablation Catheter in combination with 3D mapping system CARTO or any future development generations of this product line, provided they are CE marked and the centre has the experience of at least 10 procedures before including a patient into the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Total Procedure Duration</title>
          <population>Subjects randomized and received ablation. Modified intent-to-treat (mITT) population.</population>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="374"/>
                <count group_id="O2" value="376"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="124.4" spread="39.0"/>
                    <measurement group_id="O2" value="140.9" spread="54.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Time of Fluoroscopy</title>
        <time_frame>Fluoroscopy meter time through the initial ablation procedure</time_frame>
        <population>Subjects randomized and received ablation procedure. Modified intent-to-treat (mITT) population</population>
        <group_list>
          <group group_id="O1">
            <title>Cryoballoon Ablation</title>
            <description>Electrical isolation of the pulmonary veins: Device: ArcticFront® Cardiac CryoAblation Catheter System with the FlexCath Steerable Sheath or ArcticFront® Advance Cardiac CryoAblation Catheter System with the FlexCath Steerable Sheath or any future development generations of this product line, provided they are CE marked and the centre has the experience of at least 10 procedures before including a patient into the study.</description>
          </group>
          <group group_id="O2">
            <title>Radiofrequency Ablation</title>
            <description>Electrical isolation of pulmonary veins: Device:NaviStar® ThermoCool® Irrigated Tip Ablation Catheter in combination with 3D mapping system CARTO or any future development generations of this product line, provided they are CE marked and the centre has the experience of at least 10 procedures before including a patient into the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Total Time of Fluoroscopy</title>
          <population>Subjects randomized and received ablation procedure. Modified intent-to-treat (mITT) population</population>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="374"/>
                <count group_id="O2" value="376"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.6" spread="17.8"/>
                    <measurement group_id="O2" value="21.7" spread="13.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting a Cardiovascular Hospitalization Over the Duration of the Study.</title>
        <time_frame>33 months</time_frame>
        <population>Subjects randomized and received an ablation procedure. Modified intent-to-treat (mITT) population.</population>
        <group_list>
          <group group_id="O1">
            <title>Cryoballoon Ablation</title>
            <description>Electrical isolation of the pulmonary veins: Device: ArcticFront® Cardiac CryoAblation Catheter System with the FlexCath Steerable Sheath or ArcticFront® Advance Cardiac CryoAblation Catheter System with the FlexCath Steerable Sheath or any future development generations of this product line, provided they are CE marked and the centre has the experience of at least 10 procedures before including a patient into the study.</description>
          </group>
          <group group_id="O2">
            <title>Radiofrequency Ablation</title>
            <description>Electrical isolation of pulmonary veins: Device:NaviStar® ThermoCool® Irrigated Tip Ablation Catheter in combination with 3D mapping system CARTO or any future development generations of this product line, provided they are CE marked and the centre has the experience of at least 10 procedures before including a patient into the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting a Cardiovascular Hospitalization Over the Duration of the Study.</title>
          <population>Subjects randomized and received an ablation procedure. Modified intent-to-treat (mITT) population.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="374"/>
                <count group_id="O2" value="376"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89"/>
                    <measurement group_id="O2" value="135"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Cardiovascular Hospitalizations</title>
        <description>The total number of cardiovascular hospitalizations reported over the duration of the study.</description>
        <time_frame>33 months</time_frame>
        <population>Subjects randomized and received an ablation procedure. Modified intent-to-treat (mITT) population.</population>
        <group_list>
          <group group_id="O1">
            <title>Cryoballoon Ablation</title>
            <description>Electrical isolation of the pulmonary veins: Device: ArcticFront® Cardiac CryoAblation Catheter System with the FlexCath Steerable Sheath or ArcticFront® Advance Cardiac CryoAblation Catheter System with the FlexCath Steerable Sheath or any future development generations of this product line, provided they are CE marked and the centre has the experience of at least 10 procedures before including a patient into the study.</description>
          </group>
          <group group_id="O2">
            <title>Radiofrequency Ablation</title>
            <description>Electrical isolation of pulmonary veins: Device:NaviStar® ThermoCool® Irrigated Tip Ablation Catheter in combination with 3D mapping system CARTO or any future development generations of this product line, provided they are CE marked and the centre has the experience of at least 10 procedures before including a patient into the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Cardiovascular Hospitalizations</title>
          <description>The total number of cardiovascular hospitalizations reported over the duration of the study.</description>
          <population>Subjects randomized and received an ablation procedure. Modified intent-to-treat (mITT) population.</population>
          <units>number of cardiovascular hospitalization</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="374"/>
                <count group_id="O2" value="376"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="139"/>
                    <measurement group_id="O2" value="203"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>The duration of the study. Mean follow-up was 1.5 years, maximum follow-up was 33 months.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Cryoballoon Ablation</title>
          <description>Electrical isolation of the pulmonary veins: Device: ArcticFront® Cardiac CryoAblation Catheter System with the FlexCath Steerable Sheath or ArcticFront® Advance Cardiac CryoAblation Catheter System with the FlexCath Steerable Sheath or any future development generations of this product line, provided they are CE marked and the centre has the experience of at least 10 procedures before including a patient into the study.</description>
        </group>
        <group group_id="E2">
          <title>Radiofrequency Ablation</title>
          <description>Electrical isolation of pulmonary veins: Device:NaviStar® ThermoCool® Irrigated Tip Ablation Catheter in combination with 3D mapping system CARTO or any future development generations of this product line, provided they are CE marked and the centre has the experience of at least 10 procedures before including a patient into the study.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 17.1</default_vocab>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="129" subjects_at_risk="374"/>
                <counts group_id="E2" subjects_affected="158" subjects_at_risk="376"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>SPONTANEOUS HEMATOMA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="374"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="376"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>ANGINA PECTORIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="374"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>ANGINA UNSTABLE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="374"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>ATRIAL FIBRILLATION</sub_title>
                <counts group_id="E1" events="69" subjects_affected="54" subjects_at_risk="374"/>
                <counts group_id="E2" events="110" subjects_affected="86" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>ATRIAL FLUTTER</sub_title>
                <counts group_id="E1" events="10" subjects_affected="8" subjects_at_risk="374"/>
                <counts group_id="E2" events="13" subjects_affected="12" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>ATRIAL TACHYCARDIA</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="374"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>ATRIOVENTRICULAR BLOCK SECOND DEGREE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="374"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>BRADYCARDIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="374"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>CARDIAC FAILURE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="374"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>CARDIAC TAMPONADE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="374"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>CORONARY ARTERY DISEASE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="374"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>CORONARY ARTERY STENOSIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="374"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>MYOCARDIAL INFARCTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="374"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>PALPITATIONS</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="374"/>
                <counts group_id="E2" events="11" subjects_affected="9" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>PERICARDIAL EFFUSION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="374"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>PERICARDITIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="374"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>SICK SINUS SYNDROME</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="374"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>SUPRAVENTRICULAR EXTRASYSTOLES</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="374"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>TACHYCARDIA</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="374"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>VENTRICULAR FIBRILLATION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="374"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>VENTRICULAR TACHYCARDIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="374"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="376"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>ATRIAL SEPTAL DEFECT</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="374"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="376"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>EXOSTOSIS OF EXTERNAL EAR CANAL</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="374"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>MENIERE'S DISEASE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="374"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="376"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>THYROID CYST</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="374"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>THYROID DISORDER</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="374"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>TOXIC NODULAR GOITRE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="374"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="376"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>DACRYOSTENOSIS ACQUIRED</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="374"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>VISUAL IMPAIRMENT</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="374"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="376"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>ABDOMINAL PAIN UPPER</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="374"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>DIABETIC GASTROPARESIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="374"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>DIARRHOEA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="374"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>ENTEROCOLITIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="374"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>EPIGASTRIC DISCOMFORT</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="374"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>GASTRITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="374"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>GASTROINTESTINAL HEMORRHAGE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="374"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>HEMATOCHEZIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="374"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>IMPAIRED GASTRIC EMPTYING</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="374"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>INTESTINAL PERFORATION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="374"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>LARGE INTESTINE POLYP</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="374"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>NAUSEA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="374"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>OESOPHAGEAL ULCER</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="374"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>STASIS SYNDROME</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="374"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>VOMITING</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="374"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="376"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>ADVERSE DRUG REACTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="374"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>ASTHENIA</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="374"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>CHEST PAIN</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="374"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>DEATH</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="374"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>FATIGUE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="374"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>HERNIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="374"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>LOCAL SWELLING</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="374"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>MICROLITHIASIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="374"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>PAIN</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="374"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>PYREXIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="374"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="376"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>BILIARY COLIC</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="374"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>CHOLECYSTITIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="374"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>CHOLELITHIASIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="374"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="376"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>BRONCHITIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="374"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>DEVICE RELATED INFECTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="374"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>DIVERTICULITIS</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="374"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>INFECTIVE EXACERBATION OF CHRONIC OBSTRUCTIVE AIRWAYS DISEASE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="374"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>PNEUMONIA</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="374"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>RESPIRATORY TRACT INFECTION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="374"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>SEPSIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="374"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>TONSILLITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="374"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>URINARY TRACT INFECTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="374"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>WOUND INFECTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="374"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="376"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>ACCIDENT</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="374"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>ANESTHETIC COMPLICATION PULMONARY</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="374"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>CERVICAL VERTEBRAL FRACTURE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="374"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>CONTRAST MEDIA REACTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="374"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>CONTUSION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="374"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>FACIAL BONES FRACTURE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="374"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>FEMORAL NECK FRACTURE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="374"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>FRACTURE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="374"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>POST PROCEDURAL COMPLICATION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="374"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>POST PROCEDURAL HEMATOMA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="374"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>POST PROCEDURAL HEMORRHAGE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="374"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>PROCEDURAL DIZZINESS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="374"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>RADIUS FRACTURE</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="374"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>ROAD TRAFFIC ACCIDENT</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="374"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>SPINAL COLUMN INJURY</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="374"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>SPINAL FRACTURE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="374"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>TENDON RUPTURE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="374"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>VASCULAR PSEUDOANEURYSM</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="374"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="376"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>ARTERIOGRAM CORONARY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="374"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="376"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>HYPONATREMIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="374"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="376"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>ARTHRALGIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="374"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>BURSITIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="374"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>GROIN PAIN</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="374"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>NODAL OSTEOARTHRITIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="374"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>OSTEOARTHRITIS</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="374"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>ROTATOR CUFF SYNDROME</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="374"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>SJOGREN'S SYNDROME</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="374"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>SYNOVITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="374"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="376"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>BENIGN SALIVARY GLAND NEOPLASM</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="374"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>BREAST CANCER</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="374"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>BRONCHIAL NEOPLASM BENIGN</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="374"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>CARCINOID TUMOUR OF THE CAECUM</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="374"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>HODGKIN'S DISEASE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="374"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>LIP AND/OR ORAL CAVITY CANCER</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="374"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>METASTATIC NEOPLASM</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="374"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>PANCREATIC CARCINOMA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="374"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>THYROID NODULE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="374"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="376"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>CEREBELLAR INFARCTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="374"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>CEREBRAL HEMORRHAGE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="374"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>CRITICAL ILLNESS POLYNEUROPATHY</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="374"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>DIZZINESS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="374"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>DYSARTHRIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="374"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>EPILEPSY</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="374"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>HYPERTENSIVE ENCEPHALOPATHY</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="374"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>HYPOAESTHESIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="374"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>MIGRAINE WITH AURA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="374"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>MULTIPLE SCLEROSIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="374"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>OPTIC NEURITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="374"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>PARAPARESIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="374"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>PHRENIC NERVE PARALYSIS</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="374"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>POST PROCEDURAL STROKE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="374"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>PRESYNCOPE</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="374"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>SYNCOPE</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="374"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>TRANSIENT GLOBAL AMNESIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="374"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>TRANSIENT ISCHEMIC ATTACK</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="374"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="376"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>ANXIETY</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="374"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>DISSOCIATIVE DISORDER</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="374"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="376"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>DYSURIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="374"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>HEMATURIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="374"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>NEPHROLITHIASIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="374"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>RENAL COLIC</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="374"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>RENAL FAILURE ACUTE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="374"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>URINARY BLADDER HEMORRHAGE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="374"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="376"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>BENIGN PROSTATIC HYPERPLASIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="374"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>UTERINE PROLAPSE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="374"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>VAGINAL HEMORRHAGE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="374"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="376"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>ASPIRATION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="374"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>CHOKING</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="374"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>CHRONIC OBSTRUCTIVE PULMONARY DISEASE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="374"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>DYSPNEA</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="374"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>DYSPNEA EXERTIONAL</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="374"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>EXERTIONAL DYSPNOEA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="374"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>HEMOPTYSIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="374"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>PAINFUL RESPIRATION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="374"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>PHARYNGEAL INFLAMMATION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="374"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>PNEUMOTHORAX</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="374"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>PULMONARY CONGESTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="374"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>PULMONARY EMBOLISM</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="374"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>PULMONARY OEDEMA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="374"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>RESPIRATORY FAILURE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="374"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="376"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>HYPERHIDROSIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="374"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>PSORIASIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="374"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="376"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>BRACHYTHERAPY TO UTERUS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="374"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>CARDIAC ABLATION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="374"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>CHOLECYSTECTOMY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="374"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>HEMATOMA EVACUATION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="374"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>HOSPITALISATION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="374"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>HYSTEROSALPINGO-OOPHORECTOMY</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="374"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>RECTAL LESION EXCISION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="374"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>THORACOTOMY</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="374"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>TONSILLECTOMY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="374"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>VARICOSE VEIN OPERATION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="374"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="376"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>AORTIC ANEURYSM</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="374"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>AORTIC DISSECTION</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="374"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>ARTERIOVENOUS FISTULA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="374"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>ARTERITIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="374"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>CIRCULATORY COLLAPSE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="374"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>HEMATOMA</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="374"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>HEMORRHAGE</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="374"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>HYPERTENSION</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="374"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>HYPERTENSIVE CRISIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="374"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>VARICOSE VEIN</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="374"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>VASCULITIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="374"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>VESSEL PERFORATION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="374"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="376"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="374"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="376"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Ralf Meyer</name_or_title>
      <organization>Medtronic</organization>
      <phone>+49215981490</phone>
      <email>ralf.meyer@medtronic.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

